UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported)
|
July 17, 2023
|
|
SANUWAVE Health, Inc.
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
000-52985
|
20-1176000
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
11495 Valley View Road, Eden Prairie, Minnesota
|
55344
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code
|
(770) 419-7525
|
|
N/A
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
N/A
|
N/A
|
N/A
|
Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities
Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On July 17, 2023, SANUWAVE Health, Inc., a Nevada corporation (the “Company”), issued a press release
announcing certain preliminary financial results for the quarter ended June 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be
deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
Press release dated July 17, 2023
|
|
104
|
|
Cover Page Interactive Data File––the cover page XBRL tags are embedded within the Inline XBRL document.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SANUWAVE HEALTH, INC.
|
|
|
|
|
Dated: July 19, 2023
|
By:
|
/s/ Toni Rinow
|
|
Name:
|
Toni Rinow
|
|
Title:
|
Chief Financial Officer
|
Exhibit 99.1
SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter Ended June 30, 2023
SANUWAVE is pleased to announce preliminary revenues of $4.5 million to $4.7 million for Q2 ended June 30, 2023
Results indicate 16-21% growth rate over
Q2 2022, consistent with guidance provided in the Q1 2023 earnings release.
EDEN PRAIRIE, MN, July 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the second quarter of 2023
(ending June 30) are expected to be in the range of $4.5 to $4.7 million, which is consistent with guidance provided in the Q1 2023 earnings release.
“Despite ongoing production constraints discussed on the last earnings call, we are pleased to have been able to achieve our revenue growth
guidance previously announced for Q2 and look forward to being able to accelerate our growth rate in coming quarters,” said Morgan Frank, CEO. “The Company plans to release its full quarterly numbers for Q2 in mid-August, and we look forward to
speaking with you then to give you a more complete update on our quarterly performance and our future plans.”
The preliminary revenue results described herein are based on management’s initial analysis for the second quarter ended June 30, 2023 and may
be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating
medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing
processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as
statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current
expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s
ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks
associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues,
competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com